Please assess the completion status of the following clinical trial:

Trial Title: Safety/Proof of Concept Study of Oral QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) Mutations

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects diagnosed with LCA or RP (with a mutation in either RPE65 or LRAT)~  * Subjects with LCA must be 5-65 years of age~ * Subjects with RP must be 18-65 years of age~* Subjects who have a best-corrected visual acuity of 3 letters or better (20/800 Snellen equivalent) or viable photoreceptors on OCT/FAF.~Exclusion Criteria:~* Subjects who are actively participating in an experimental therapy study or who have received experimental therapy within 60 days of Day 0.~* Subjects with any clinically important abnormal physical finding at Screening.~* Subjects who have taken any prescription or investigational oral retinoid medication (e.g., Accutane,® Soriatane®) within 6 months of Day 0 and subjects who did not tolerate their previous oral retinoid medication will be excluded regardless of the time of last exposure.~* Subjects with a history of diabetes or chronic hyperlipidemia, hepatitis, pancreatitis, or cirrhosis.~* Subjects who have taken any supplements containing ≥10,000 IU vitamin A within 60 days of screening

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).